Sanofi-logo

For US Healthcare Professional use only.
The safety and efficacy of these investigational agents have not been established.
Asthma

Proof-of-concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy

Proof-of-concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy
Proof-of-concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy Scan and Download Back

Privacy & Data Protection        Cookies Policy
Does not include study cards for clinical programs of dupilumab.

MAT-US-2401225 v1.0 - P Exp. Date: 02/12/2026
© 2024 Sanofi. All rights reserved.